South & Central America Clinical Trials Market Forecast to 2028
South & Central America Clinical Trials Market Forecast to 2028 – Regional Analysis – by Study Design (Interventional, Observational, and Expanded Access), Phase (Phase I, Phase II, Phase III, and Phase IV), and Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials Fuels South & Central America Clinical Trials Market
In decentralized clinical trials (DCT), patients’ physical access to hospital-based trial sites is reduced or eliminated. In DCTs, digital technologies are used to enable access of patients to clinical research, remote data collection and monitoring, and communication between investigators and participants. A hybrid clinical trial approach combines home-based and on-site activities, bringing the best patient experience and meeting complex protocol regimes, gaining traction across various therapeutic areas and trial phase journeys. Initially, due to challenges such as patient privacy, data security, regulatory barriers, and complex protocol regimes, the adoption of DCT was affected. However, due to the COVID-19 pandemic, the sponsors of clinical trials adopted decentralized and hybrid clinical techniques for developing drugs. They could not continue with traditional trials as they required in-person visits. Due to the restrictions for travel, the only way to gather data and keep trials going was to work remotely and adopt technology much faster than they would have otherwise. Therefore, decentralization broadens trial access to reach a larger number and potentially a more diverse pool of patients.
Further, hybrid clinical trials allow sponsors to strategically incorporate decentralized clinical trial (DCT) elements into study designs. These trial models offer unprecedented flexibility, so more companies are interested in hybrid trials, and the resulting growth is redefining the industry landscape. According to ObvioHealth, the FDA plans to unveil protocols in 2023 to support the use of DCT methods, inspiring confidence in these components for future clinical research. Thus, the increasing focus on using decentralized and hybrid clinical trials over traditional clinical trial methods is expected to provide lucrative opportunities for the clinical trials market during the forecast period.
South & Central America Clinical Trials Market Overview
The South & Central America clinical trials market is segmented into Brazil, Argentina, and the Rest of South & Central America. South & Central America occupies a significant position in the clinical trials market and is estimated to register a robust growth rate over the forecast period. The growth is due to growing clinical trials, key innovation by market players of clinical trial process, and government initiatives to support the clinical trial fuels the market growth.
South & Central America Clinical Trials Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Clinical Trials Market Segmentation
The South & Central America clinical trials market is segmented into phase, study design, indication, and country.
Based on phase, the South & Central America clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest South & Central America clinical trials market share in 2022.
Based on study design, the South & Central America clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest South & Central America clinical trials market share in 2022.
Based on indication, the South & Central America clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest South & Central America clinical trials market share in 2022.
Based on country, the South & Central America clinical trials market has been categorized into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America clinical trials market share in 2022.
Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the South & Central America clinical trials market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team research, the South & Central America clinical trials market was valued at US$ 1,794.69 million in 2022 and is expected to reach US$ 2,523.98 million by 2028, registering a CAGR of 5.8% from 2022 to 2028. Increasing adoption and outsourcing of clinical trials and flourishing pharmaceutical industry and increasing R&D activities in pharmaceutical industry are the critical factors attributed to the South & Central America clinical trials market expansion.
Adoption of Artificial Intelligence (AI) offers innovative ways to collect and manage clinical trial data and reduces dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process.
The Oncology Data Science team at AstraZeneca feeds these data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per “GOFAIR (Findability, Accessibility, Interoperability, and Reuse of digital assets)”—the set of principles. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company’s drug development teams in compliance with data protection laws.
AstraZeneca has collaborated with companies such as Tempus to leverage real-world data and represent patients globally. Such strategic partnerships are anticipated to offer crucial evidence about patient outcomes without revealing the identification of the clinical trial participants in the datasets.
Moreover, with the power of AI, companies can rapidly digitize clinical-trial processes to complete studies faster. Life-saving medicines and treatments can be provided to patients more quickly, and life sciences companies could gain a competitive edge. Thus, the increasing application coupled with rising investments in AI for processing clinical trial data is likely to boost the South & Central America clinical trial market growth in the coming years.
On the contrary, expensive and time-consuming process hurdles the growth of South & Central America clinical trials market.
Based on phase, the South & Central America clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment held 53.7% share of South & Central America clinical trials market in 2022, amassing US$ 963.06 million. It is projected to garner US$ 1,362.96 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on study design, the South & Central America clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held 47.3% share of South & Central America clinical trials market in 2022, amassing US$ 848.91 million. It is projected to garner US$ 1,212.01 million by 2028 to expand at 6.1% CAGR during 2022–2028.
Based on Indication, the South & Central America clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held 30.1% share of South & Central America clinical trials market in 2022, amassing US$ 540.36 million. It is projected to garner US$ 790.17 million by 2028 to expand at 6.5% CAGR during 2022–2028.
Based on country, the South & Central America clinical trials market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.0% share of South & Central America clinical trials market in 2022. It was assessed at US$ 682.52 million in 2022 and is likely to hit US$ 941.70 million by 2028, exhibiting a CAGR of 5.5% during 2022–2028.
Key players operating in the South & Central America clinical trials market are Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, and Thermo Fisher Scientific Inc., among others.
In Feb 2023, Parexel launched a new expert series, New Medicines, Novel Insights. The series features fresh insights from the company’s global, cross-functional experts analyzing drug development trends and offering evidence-based guidance to the biopharmaceutical industry.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America clinical trials market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America clinical trials market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the clinical trials market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Clinical Trials Market – By Phase
1.3.2 South & Central America Clinical Trials Market – By Study Design
1.3.3 South & Central America Clinical Trials Market – By Indication
1.3.4 South & Central America Clinical Trials Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Clinical Trials Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South And Central America PEST Analysis
4.3 Experts Opinion
5. South & Central America Clinical Trials Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
5.2 Market Restraints
5.2.1 Expensive and Time-Consuming Process
5.3 Market Opportunities
5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
5.4 Future Trends
5.4.1 AI-Driven Clinical Trials
5.5 Impact Analysis
6. Clinical Trials Market – South & Central America Analysis
6.1 South & Central America Clinical Trials Market Revenue Forecast and Analysis
7. South & Central America Clinical Trials Market Revenue and Forecast To 2028 – by Study Design
7.1 Overview
7.2 South & Central America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
7.3 Interventional
7.3.1 Overview
7.3.2 Interventional: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Observational
7.4.1 Overview
7.4.2 Observational: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Expanded Access
7.5.1 Overview
7.5.2 Expanded Access: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Clinical Trials Market – By Phase
8.1 Overview
8.2 South & Central America Clinical Trials Market, by Phase, 2022 and 2028 (%)
8.3 Phase III
8.3.1 Overview
8.3.2 Phase III: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Phase II
8.4.1 Overview
8.4.2 Phase II: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Phase IV
8.5.1 Overview
8.5.2 Phase IV: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Phase I
8.6.1 Overview
8.6.2 Phase I: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Clinical Trials Market Revenue and Forecast To 2028 – Indication
9.1 Overview
9.2 South & Central America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
9.3 Autoimmune/Inflammation
9.3.1 Overview
9.3.2 Autoimmune/Inflammation: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Pain Management
9.4.1 Overview
9.4.2 Pain Management: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Oncology
9.5.1 Overview
9.5.2 Oncology: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.6 CNS Condition
9.6.1 Overview
9.6.2 CNS Condition: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Diabetes
9.7.1 Overview
9.7.2 Diabetes: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Obesity
9.8.1 Overview
9.8.2 Obesity: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Cardiovascular
9.9.1 Overview
9.9.2 Cardiovascular: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.10 Other
9.10.1 Overview
9.10.2 Other: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Clinical Trials Market – Revenue and Forecast to 2028 – Country Analysis
10.1 South & Central America Clinical Trials Market
10.1.1 Overview
10.1.2 South & Central America: Clinical Trials Market, by Country, 2022 & 2028 (%)
10.1.2.1 Brazil: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 Brazil: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 Brazil: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.2.1.4 Brazil: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.2.1.5 Brazil: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.2.2 Argentina: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Argentina: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 Argentina: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.2.2.4 Argentina: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.2.2.5 Argentina: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.2.3 Rest of South & Central America: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 Rest of South & Central America: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 Rest of South & Central America: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.2.3.4 Rest of South & Central America: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.2.3.5 Rest of South & Central America: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 IQVIA Holdings Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Parexel International Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ICON Plc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 SGS SA
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Syneos Health Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Thermo Fisher Scientific Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6
12.7.7 Key Developments
12.8 Laboratory Corp of America Holdings
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About Research Team
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Brazil Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 2. Brazil Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 4. Argentina Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 5. Argentina Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 6. Argentina Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 7. Rest of South & Central America Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 8. Rest of South & Central America Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 9. Rest of South & Central America Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 10. Organic Developments Done by Companies
Table 11. Inorganic Developments Done by Companies
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. South & Central America Clinical Trials Market Segmentation
Figure 2. South & Central America Clinical Trials Market, By Region
Figure 3. South & Central America Clinical Trials Market Overview
Figure 4. Phase III Segment Held Largest Share of Phase Segment in South & Central America Clinical Trials Market
Figure 5. Argentina is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. South And Central America: PEST Analysis
Figure 7. South & Central America Experts Opinion
Figure 8. Impact Analysis
Figure 9. South & Central America Clinical Trials Market– Revenue Forecast and Analysis – 2020- 2028
Figure 10. South & Central America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
Figure 11. Interventional: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Observational: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Expanded Access: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. South & Central America Clinical Trials Market, by Phase 2022 and 2028 (%)
Figure 15. Phase III: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Phase II: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Phase IV: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Phase I: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. South & Central America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
Figure 20. Autoimmune/Inflammation: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Pain Management: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Oncology: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. CNS Condition: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Diabetes: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Obesity: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Cardiovascular: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Other: South & Central America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. South & Central America: Clinical Trials Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29. South & Central America: Clinical Trials Market, by Country, 2022 & 2028 (%)
Figure 30. Brazil: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Argentina: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Rest of South & Central America: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – South & Central America Clinical Trials Market
o Charles River Laboratories International Inc
o ICON Plc
o IQVIA Holdings Inc
o Laboratory Corp of America Holdings
o Parexel International Corp
o SGS SA
o Syneos Health Inc
o Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.